Teva Pharmaceutical Industries Ltd (TEVA): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Teva Pharmaceutical Industries ( TEVA) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.8%. By the end of trading, Teva Pharmaceutical Industries fell $0.54 (-1.4%) to $38.34 on average volume. Throughout the day, 2,824,778 shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 3,362,200 shares. The stock ranged in price between $38.19-$38.85 after having opened the day at $38.51 as compared to the previous trading day's close of $38.88. Other companies within the Drugs industry that declined today were: AVANIR Pharmaceuticals ( AVNR), down 18.2%, Galena Biopharma ( GALE), down 14.9%, Galectin Therapeutics ( GALT), down 9.6% and Prana Biotechnology ( PRAN), down 8.9%.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $32.5 billion and is part of the health care sector. Shares are up 3.1% year to date as of the close of trading on Thursday. Currently there are 8 analysts that rate Teva Pharmaceutical Industries a buy, 1 analyst rates it a sell, and 12 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity.

On the positive front, GW Pharmaceuticals PLC ADR ( GWPH), up 55.8%, ViroPharma ( VPHM), up 28.4%, Rockwell Medical ( RMTI), up 22.8% and Genvec ( GNVC), up 22.7% , were all gainers within the drugs industry with Shire ( SHPG) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists